News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Anacor Pharmaceuticals, Inc. Reports First Quarter 2012 Financial Results



5/11/2012 10:52:59 AM

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the first quarter ended March 31, 2012. “Our Phase 3 trials of tavaborole in onychomycosis are progressing well, with retention and compliance rates performing better than our assumptions. We are looking forward to reporting data from our first Phase 3 trial in January 2013,” said David Perry, CEO of Anacor Pharmaceuticals. “We are also preparing to initiate additional Phase 2 trials of AN2728 in atopic dermatitis and expect to have data from one of these trials in the second half of this year.”

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES